Table 8

Comparison of FSFI scores according to disease characteristics
Item Post-diagnosis Post-chemotherapy Reduction (%) p*
Median (IQR) Median (IQR)
Clinical stage
  II A–B (n=8) 14.8 (14.5 – 19.0) 9.8 (7.2 – 12.1) 33.8 0.012
  III A–B (n=16) 8.5 (2.6 – 16.4) 2 (2 – 8) 76.5 0.002
  p 0.052 0.016
Tumor size
  T2 (n=8) 14.8 (14.5 – 19.0) 9.8 (7.2 – 12.1) 33.8 0.012
  T3 (n=6) 10.5 (6.6 – 18.2) 4.6 (2.0 – 9.1) 56.2 0.028
  T4 (n=10) 8.5 (2 – 15.6) 2 (2 – 8) 76.5 0.028
  p 0.301 0.132
  Receptor / HER2/neu status
  ER+/PR+/HER2+ (n=1) 8.8 (8.8 – 8.8) 8 (8 – 8) 9.1 -
  ER+/PR–/ HER2+ (n=0) - - - -
  ER+/PR+/HER2– (n=9) 12.8 (5.0 – 14.8) 7.2 (2 – 9.6) 43.8 0.018
  ER+/PR–/HER2– (n=4) 18.5 (8 – 20.8) 6.0 (2 – 11.8) 67.6 0.068
  ER–/PR+/HER2+ (n=0) - - - -
  ER–/PR–/HER2+ (n=2) 11.4 (2 – 20.7) 2 (2 – 2) 82.5 0.317
  ER–/PR+/HER2– (n=0) - - - -
  ER–/PR–/HER2– (n=8) 13.5 (5.0 – 18.7) 5 (2 – 9.7) 63.0 0.018
  p 0.688 0.677
Histologic grade
  Grade I (n=1) 15 (15 – 15) 7.2 (7.2 – 7.2) 52.0 -
  Grade II (n=17) 14.5 (7.6 – 18.5) 7.2 (2 – 10.6) 50.3 0.001
  Grade III (n=6) 6.5 (2 – 15.8) 2 (2 – 8.4) 69.2 0.068
  p 0.362 0.489
Prior diagnosis
  No (n=19) 14.5 (4.2 – 17.6) 7.2 (2 – 9.9) 50.3 0.001
  Yes (n=5) 8.8 (7.7 – 17.1) 2 (2 – 8) 77.3 0.043
  p 0.406 0.891

T2 = 2–5 cm; T3 = >5 cm; T4 = inflammatory tumor or invasion of chest wall or skin.

ER, estrogen receptor; PR, progesterone receptor.

*Wilcoxon test.

Mann–Whitney U.

Kruskal-Wallis test.

Cavalheiro et al.

Cavalheiro et al. BMC Women's Health 2012 12:28   doi:10.1186/1472-6874-12-28

Open Data